Picture of Anthem Biosciences logo

ANTHEM — Anthem Biosciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

India's Anthem Biosciences rises as Jefferies initiates coverage with 'buy' rating

BUZZ-India's Anthem Biosciences rises as Jefferies initiates coverage with 'buy' rating

** Drug research and manufacturing company Anthem Biosciences ANTH.NS shares rise as much as 2.3% to 894.90 rupees

** Jefferies initiates coverage with "Buy" rating and a PT of 1,050 rupees

** The PT represents a 20.1% upside to the stock's last close

** Brokerage expects Anthem to deliver strong revenue and profit growth over FY26-29, supported by its expanding business and project pipeline.

** Jefferies says growth should be supported by rising production of commercial products and a solid pipeline of projects in advanced stages of development

** ANTH trades at forward 12-month PE of 63.48 vs industry median of 26.95

** All of 8 brokerages covering the stock rate it "buy" or higher; their median PT is 900 rupees

** YTD, stock up 35.3%


(Reporting by Abhinav Parmar in Bengaluru)

((Abhinav.Parmar@thomsonreuters.com;))

Recent news on Anthem Biosciences

See all news